EXTH-15. TARGETING ANDROGEN SIGNALING IN GLIOBLASTOMA (GBM) USING SEVITERONEL (SEVI), A CYP17 LYASE AND ANDROGEN RECEPTOR (AR) INHIBITOR, ALONE AND IN COMBINATION WITH RADIATION (RT)

Summary: CYP17A1 is a key enzyme in steroidogenesis and is associated with hormone-dependent cancers. The discovery and development of CYP17A1 inhibitors has been a focus in medicinal chemistry, particularly for treating castration-resistant prostate cancer. This Perspective discusses non-steroidal CYP17A1 inhibitors, emphasizing the target's structure, key findings from different compounds, and design principles for future inhibitors.